Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
D

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/Targeted Therapy, What's the "Right" Frontline Therapy, TMB, Wild Type Disease, Potential Biomarker for Long-Term Benefit

By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
Skin
14:32
Xth Eurasian Hematology-Oncology Congress

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Feat. Z. Turna
06:35
Xth Eurasian Hematology-Oncology Congress

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Feat. Z. Turna
21:19
Xth Eurasian Hematology-Oncology Congress

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Feat. S. Seber
05:25
Xth Eurasian Hematology-Oncology Congress

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Feat. D. Erdem
15:44
Xth Eurasian Hematology-Oncology Congress

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Feat. D. Erdem